J&J’s HIV vaccine fails phase 2b, extending long wait for an effective jab
The wait for an HIV vaccine goes on. Johnson & Johnson, having seen peers including Merck swing at HIV and miss, has reported the failure of a vaccine based on similar technology to its COVID-19 jab to protect women from infection with the virus.